– Reuters
Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts
Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.
Related Posts
Netflix Analyst Gains Conviction On Longer-Term Upside Potential From Ad Revenue, Upgrades Stock
Macquarie analyst Tim Nollen upgraded Netflix, Inc (NASDAQ:NFLX) to Neutral from Underperform with a price target of $230, up from $170, as he…
American Airlines Pilots Reach Deal With Management On Proposed Tentative Agreement 2.0
American Airlines Group Inc (NASDAQ: AAL) pilots union reached an
B of A Securities Upgrades Golar LNG to Buy, Raises Price Target to $29
B of A Securities analyst Ken Hoexter upgrades Golar LNG (NASDAQ:GLNG) from Neutral to Buy and raises the price target from $23 to $29.